RxDoctor Payments Data

Colin Stroh, PA

Physician Assistant · Allentown, PANPI 1265914964

Payments from drug & device makers

$5,604in general payments, 2019–2025

Across 91 payments — averaging $61.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$651
  • E.r. Squibb & Sons, L.L.C.$480
  • Regeneron Healthcare Solutions, Inc.$409
  • Gilead$401
  • Intra-sana Laboratories$200
  • plus $889 from 7 others

What the payments were for

  • Food & beverage$5,42997%
  • Education$751%
  • Gifts$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,604 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$53,455
Medicare patients
445
Services billed
601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase57$186,061
LinzessLinaclotide133$107,533
XifaxanRifaximin33$92,486
ZenpepLipase/Protease/Amylase20$51,997
ViberziEluxadoline14$18,878
Dexlansoprazole DrDexlansoprazole56$15,914
MotegrityPrucalopride Succinate19$15,507
Mesalamine18$11,077
Pantoprazole Sodium732$9,375
Sucralfate44$6,020
Omeprazole530$5,987
Colestipol Hcl42$3,895
CholestyramineCholestyramine (With Sugar)37$3,634
Cholestyramine LightCholestyramine30$2,849
Famotidine248$2,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$2,574$312,472204 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$651$92,48633 claims
Aimmune Therapeutics, Inc.Zenpep$125$51,99720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →